Precision BioSciences Inc DTIL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
-
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
-
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
-
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
-
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
Trading Information
- Previous Close Price
- $6.17
- Day Range
- $5.72–6.18
- 52-Week Range
- $3.53–9.62
- Bid/Ask
- $5.78 / $6.86
- Shares Outstanding
- 27.60M
- Market Cap
- $159.26M
- Volume/Avg
- 300,248 / 269,866
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.76
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 67
Valuation
|
Metric
|
DTIL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.56 |
Price/Sales | 2.76 |
Price/Cash Flow | — |
Price/Earnings
DTIL
Financial Strength
|
Metric
|
DTIL
|
|---|---|
Quick Ratio | 12.26 |
Current Ratio | 12.82 |
Interest Coverage | −42.42 |
Quick Ratio
DTIL
Profitability
|
Metric
|
DTIL
|
|---|---|
Return on Assets (Normalized) | −28.37% |
Return on Equity (Normalized) | −67.27% |
Return on Invested Capital (Normalized) | −50.00% |
Return on Assets
DTIL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|WzKQ>FP | LOCK|?$>?Q | $127B | |||
| Moderna Inc
MRNA
| LOCK|?<znZ? | LOCK|T^^ | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|ZGQp%<z | LOCK|j$FN | $81B | |||
| argenx SE ADR
ARGX
| LOCK|Yp@XD?? | LOCK|>&s | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|z^>pmkb | LOCK|!&J | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|XD$%VgL | LOCK|vPN$ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|s!LQw#Q& | LOCK|Md#ch | $27B | |||
| Incyte Corp
INCY
| LOCK|vmRt<g | LOCK|$% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|mnkmy# | LOCK|Krr | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@QS^jk | LOCK|K!Y | $14B |
United States